JACC. Case reports · 2026
Percutaneous Tricuspid Valve-in-Valve Implantation With Melon Seeding During Deployment.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sellers Alexander M, Ravat Shreyas, Bennetts Jayme, Roberts-Thomson Ross, Khan Ehsan, Engela Jean, Langran Jayne, Sinhal Ajay R
Аннотация
BACKGROUND: Bioprosthetic tricuspid valves are prone to structural deterioration over time. In patients with multiple prior sternotomies and functioning left-sided prostheses, repeat surgery may carry prohibitive risk, prompting consideration of transcatheter alternatives.
CASE SUMMARY: A 42-year-old patient with rheumatic heart disease and a history of 3 prior sternotomies for mitral, aortic, and tricuspid valve replacement presented with recurrent admissions for diuretic-resistant right heart failure complicated by congestive hepatopathy (Child-Pugh B cirrhosis). Imaging demonstrated severe stenosis of a bioprosthetic tricuspid valve, with preserved left-sided valve function. The patient underwent successful percutaneous tricuspid valve-in-valve implantation, resulting in marked symptomatic improvement and significant reduction in transvalvular gradients on echocardiography.
DISCUSSION: Current guidelines support reintervention for symptomatic bioprosthetic valve dysfunction. In high surgical risk patients, percutaneous tricuspid valve-in-valve implantation represents an effective and less invasive alternative to repeat surgery.
TAKE-HOME MESSAGE: Percutaneous tricuspid valve-in-valve replacement is a viable therapeutic option for failed tricuspid bioprostheses in carefully selected high-risk patients.
CASE SUMMARY: A 42-year-old patient with rheumatic heart disease and a history of 3 prior sternotomies for mitral, aortic, and tricuspid valve replacement presented with recurrent admissions for diuretic-resistant right heart failure complicated by congestive hepatopathy (Child-Pugh B cirrhosis). Imaging demonstrated severe stenosis of a bioprosthetic tricuspid valve, with preserved left-sided valve function. The patient underwent successful percutaneous tricuspid valve-in-valve implantation, resulting in marked symptomatic improvement and significant reduction in transvalvular gradients on echocardiography.
DISCUSSION: Current guidelines support reintervention for symptomatic bioprosthetic valve dysfunction. In high surgical risk patients, percutaneous tricuspid valve-in-valve implantation represents an effective and less invasive alternative to repeat surgery.
TAKE-HOME MESSAGE: Percutaneous tricuspid valve-in-valve replacement is a viable therapeutic option for failed tricuspid bioprostheses in carefully selected high-risk patients.